NCT06351592 - First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 28, 2024

Primary Completion Date

April 26, 2029

Study Completion Date

April 26, 2029

Conditions

Amyotrophic Lateral Sclerosis (ALS)Mutation in the Superoxide Dismutase-1 (SOD1) Gene

Interventions

DRUG

ALN-SOD

Administered by intrathecal (IT) injection

OTHER

Diluent

Administered by IT injection

DRUG

Placebo (PB)

Administered by IT injection

Trial Locations (14)

2109

RECRUITING

Macquarie University, Sydney

2139

RECRUITING

Concord Repatriation General Hospital, Concord

3080

RECRUITING

Seoul National University Hospital, Seoul

4575

RECRUITING

Sunshine Coast University Hospital, Birtinya

11211

RECRUITING

Taipei Veterans General Hospital, Taipei

T6G 2G3

RECRUITING

University of Alberta Hospital, Edmonton, Division of Neurology, Edmonton

N6A 5A5

RECRUITING

University Hospital - London Health Sciences Centre, London

M4N3M5

RECRUITING

Sunnybrook Research Institute, Toronto

H3A 2B4

RECRUITING

Montreal Neurological Institute and Hospital, Montreal

060-8648

RECRUITING

Hokkaido University Hospital, Sapporo

770-0042

RECRUITING

Tokushima University Hospital, Tokushima

143-8541

RECRUITING

Toho University Omori Medical Center, Ōta-ku

606-8507

RECRUITING

Kyoto University Hospital, Kyoto

04763

RECRUITING

Hanyang University Seoul Hospital, Seoul

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY